Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response
Allergy · 2024-12 · 79 (12) · 3448-3463
DOI: 10.1111/all.16261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 02.08.2024. Verfasst von Francisca Molina-Jiménez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biology Unit, Hospital Universitario de la Princesa, Madrid, Spain. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Proton Pump Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
Recently, we have identified a dysregulated protein signature in the esophageal epithelium of eosinophilic esophagitis (EoE) patients including proteins associated with inflammation and epithelial barrier function; however, the effect of proton pump inhibitor (PPI) treatment on this signature is unknown. Herein, we used a proteomic approach to investigate: (1) whether PPI treatment alters the esophageal epithelium protein profile observed in EoE patients and (2) whether the protein signature at baseline predicts PPI response.
Methods
We evaluated the protein signature of esophageal biopsies using a cohort of adult EoE ( n = 25) patients and healthy controls (C) ( n = 10). In EoE patients, esophageal biopsies were taken before (pre) and after (post) an 8‐week PPI treatment, determining the histologic response. Eosinophil count PostPPI was used to classify the patients: ≥15 eosinophils/hpf as non‐responders (non‐responder) and < 15 eosinophils/hpf as responders (R). Protein signature was determined and differentially accumulated proteins were characterized to identify altered biological processes and signaling pathways.
Results
Comparative analysis of differentially accumulated proteins between groups revealed common signatures between three groups of patients with inflammation (responder‐PrePPI, non‐responder‐PrePPI, and non‐responder‐PostPPI) and without inflammation (controls and responder‐PostPPI). PPI therapy almost reversed the EoE specific esophageal protein signature, which is enriched in pathways associated with inflammation and epithelial barrier function, in responder‐PostPPI. Furthermore, we identified a set of candidate proteins to differentiate responder‐PrePPI and non‐responder‐PrePPI EoE patients before treatment.
Conclusion
These findings provide evidence that PPI therapy reverses the alterations in esophageal inflammatory and epithelial proteins characterizing EoE, thereby providing new insights into the mechanism of PPI clinical response. Interestingly, our results also suggest that PPI response could be predicted at baseline in EoE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Biology Unit, Hospital Universitario de la Princesa, Madrid, Spain.
- Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP), Madrid, Spain.
- Department of Gastroenterology, Hospital General de Tomelloso, Ciudad Real, Spain.
- Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
- Department of Gastroenterology, Hospital Universitario de La Princesa, Madrid, Spain.
ORCID-Profile: Francisca Molina-Jiménez, Lola Ugalde-Triviño, Laura Arias-González, Elisa Armenteros, Carlos Relaño-Rupérez, Sergio Casabona, José Andrés Moreno-Monteagudo, María Teresa Pérez-Fernández, Verónica Martín-Domínguez, Jennifer Fernández-Pacheco, Emilio José Laserna-Mendieta, Patricia Muñoz-Hernández, Jorge García-Martínez, Javier Muñoz, Alfredo J Lucendo, Cecilio Santander, Pedro Majano
Förderung
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España
- Instituto de Salud Carlos III
Zitieren
APA
Molina-Jiménez, F., Ugalde-Triviño, L., Arias-González, L., Armenteros, E., Relaño-Rupérez, C., Casabona, S., Moreno-Monteagudo, J. A., Pérez-Fernández, M. T., Martín-Domínguez, V., Fernández-Pacheco, J., Laserna-Mendieta, E. J., Muñoz-Hernández, P., García-Martínez, J., Muñoz, J., Lucendo, A. J., Santander, C., & Majano, P. (2024). Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response. Allergy, 79(12), 3448-3463. https://doi.org/10.1111/all.16261
Vancouver
Molina-Jiménez F, Ugalde-Triviño L, Arias-González L, Armenteros E, Relaño-Rupérez C, Casabona S, et al. Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response. Allergy. 2024;79(12):3448-3463. doi:10.1111/all.16261
BibTeX
@article{MolinaJimnez2024,
author = {Molina-Jiménez, Francisca and Ugalde-Triviño, Lola and Arias-González, Laura and Armenteros, Elisa and Relaño-Rupérez, Carlos and Casabona, Sergio and Moreno-Monteagudo, José Andrés and Pérez-Fernández, María Teresa and Martín-Domínguez, Verónica and Fernández-Pacheco, Jennifer and Laserna-Mendieta, Emilio José and Muñoz-Hernández, Patricia and García-Martínez, Jorge and Muñoz, Javier and Lucendo, Alfredo J and Santander, Cecilio and Majano, Pedro},
title = {Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response},
journal = {Allergy},
year = {2024},
volume = {79},
number = {12},
pages = {3448--3463},
doi = {10.1111/all.16261}
}
EUVIMED